Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAERUS trial of trastuzumab deruxtecan for ctDNA-defined molecular progression in HR-positive, HER2-low metastatic breast cancer
jRCT2051260024Phase 2Recruiting
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in breast cancer (2 arms), sponsored by none. Primary endpoint: Proportion of patients achieving molecular complete response at 24 weeks after registration. Started Jul 2026; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2051260024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260024.